New Data Utilizing the Eeva™ Technology to be presented at the American Society for Reproductive Medicine 2013 Annual Meeting

   New Data Utilizing the Eeva™ Technology to be presented at the American
            Society for Reproductive Medicine 2013 Annual Meeting

PR Newswire

BOSTON and MENLO PARK, Calif., Oct. 10, 2013

BOSTON and MENLO PARK, Calif., Oct. 10, 2013 /PRNewswire/-- Auxogyn, Inc., a
leader in reproductive health that provides novel scientific and clinically
validated solutions to in vitro fertilization (IVF) clinicians and their
patients, today announced upcoming presentations of the latest research data
on its Eeva™ Technology the American Society for Reproductive Medicine (ASRM)
Annual Meeting. The meeting is being held October 12-17 in Boston.

"We are pleased that our Eeva Technology and resulting clinical data will be
so prominently represented at the upcoming ASRM Annual Meeting," stated Lissa
Goldenstein, President and CEO of Auxogyn. "Auxogyn remains committed to
supporting the pursuit of clinical research with the goal of improving
clinical care and outcomes for women undergoing IVF."

Notable data from Auxogyn at ASRM 2013 include:

  oEmbryos Exhibiting Abnormal First Cytokinesis Phenotypes Are Associated
    With Poorer Embryo Development And Lower Implantation Potential – Tuesday,
    October 15, 4:15-4:30 p.m. EDT (oral presentation - P-327)

       oMultisite retrospective cohort study to determine the incidence of a
         novel abnormal first cytokinesis phenotype evaluated during the first
         cytokinesis and assessed clinical relevance

  oEmbryo Cleavage Kinetics Under Different Oxygen Tensions Predict Embryonic
    Developmental Potential In The Mouse – Tuesday, October 15, 7:00-8:45 a.m.
    EDT (poster - P-371)

       oLaboratory research to determine ability of early cytokinesis events
         measured by time-lapse microscope to predict mouse blastocyst

  oBlastocyst Development Of Rhesus Macaque Embryos Produced By
    Intracytoplasmic Sperm Injection (ICSI) Is Dependent On Early Cytokinesis
    – Tuesday, October 15, 7:00-8:45 a.m. EDT (poster - P-330)

       oProspective study to determine similarity of early developmental
         events in rhesus macaque embryos to human embryos and whether
         predictive parameters for blastocyst development could be determined
         with novel use of time-lapse imagery to evaluate macaque embryos

  oEarly Times To Cavitation Are Associated With A Reduced Prevalence Of
    Aneuploidy In Embryos Cultured To The Blastocyst Stage – A Prospective
    Blinded Morphokinetic Study – Wednesday, October 16, 7:00-8:30 a.m. EDT
    (poster - P-811)

       oProspective study to evaluate relationship factors influencing
         embryonic reproductive competence such as early cleavage rates and

  oElucidating How Fragmentation And Other Blastomere Dynamics Affect Embryo
    Development And Clinical Outcomes – Tuesday, October 15, 12:00 PM – 12:45
    PM EDT (video summary)

       oStudy utilizing time-lapse imaging to understand how dynamic
         morphological features, such as fragmentation, impact embryonic
         health and clinical outcomes

  oUsing A Novel Time-Lapse Platform With Automated Image Analysis Can Detect
    Diverse Abnormal Cleavage Patterns That Are Not Recognized By Traditional
    Morphology And Correlate With Poor Implantation – Thursday, October 17,
    7:00-8:45 a.m. EDT (poster - P-1091)

       oRetrospective cohort study assessing the clinical relevance of zygote
         AC (AC1) and daughter cell AC (AC2) to examine the potential of using
         automated time-lapse cleavage analysis to deselect AC

Please note that all abstracts are embargoed until the date and time of

Auxogyn is also sponsoring a seminar covering the latest information on embryo

  oDevelopment and Application Of The First Embryo Assessment Test:
    Time-Lapse Enabled Technology, Clinical Validation and Generalization –
    Monday, October 14, 7:00-9:00 p.m. EDT (Seaport Boston World Trade Center)

Full session details and data presentation listings for the 2013 meeting can
be found on the ASRM website at

About Auxogyn
Auxogyn is a leader in reproductive health that provides novel scientific and
clinically validated solutions to IVF clinicians and their patients by
translating scientific discoveries in early embryo development into clinical
tools. The Company's flagship product, the Eeva™ Test, delivers objective
information regarding embryo development that IVF clinicians and patients can
use to make important treatment decisions. Auxogyn is privately held and
funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and
TPG Biotech. For more information visit and follow us on Twitter

About the Eeva™ Test
The Eeva Test provides IVF clinicians with information about the embryo's
development potential. Eeva proprietary software automatically analyzes embryo
development against scientifically validated cell-division parameters
conceived by researchers at Stanford University in the US. With results from
the Eeva Test, IVF teams will have morphological assessment and objective
information to aid their embryo selection decisions. The Eeva Test was
evaluated in a prospective, multi-center, 160-patient prospective multi-center
trial with ~1,800 embryos.Results of this study were presented in July 2012
at the European Society of Human Reproduction and Embryology (ESHRE) Annual
Meeting and published by Conaghan et al in Fertility and Sterility, May 2013.

The Eeva Test is currently CE Marked and available for use in the EU and
authorized by Health Canada for sale in Canada. The FDA submission is pending
and Eeva is not available for sale in the United States. For a full list of
clinics in the EU offering the Eeva Test please visit or
follow us on Twitter @EevaIVF.

SOURCE Auxogyn

Contact: Robert Stanislaro, FTI Consulting,, +1 (212) 850-5657
Press spacebar to pause and continue. Press esc to stop.